Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group
| Autor: | Eiichi Ishii, Daisuke Tomizawa, Tomoko Kuno, Shuki Mizutani, Katsuyoshi Koh, Tatsutoshi Nakahata, Jun Nagayama, Atsushi Ogawa, Tomoko Kishimoto, Kanji Sugita, Takashi Sato, Yoshihiro Takahashi, Noriko Hotta, Yoshihisa Nagatoshi, Kohji Kato, Keizo Horibe |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Oncology
Male medicine.medical_specialty medicine.medical_treatment Immunology Biochemistry Germline Disease-Free Survival Japan hemic and lymphatic diseases Acute lymphocytic leukemia Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Retrospective Studies Chemotherapy business.industry Remission Induction Infant Retrospective cohort study Cell Biology Hematology Histone-Lysine N-Methyltransferase medicine.disease Chemotherapy regimen Burkitt Lymphoma Clinical trial Survival Rate Leukemia Female business Myeloid-Lymphoid Leukemia Protein |
| Zdroj: | Blood. 107(12) |
| ISSN: | 0006-4971 |
| Popis: | Although infants with acute lymphoblastic leukemia (ALL) and a germline MLL gene have a better prognosis than comparable infants with a rearranged MLL gene, their optimal therapy is controversial. In 2 consecutive studies, conducted between 1996 and 2002, we treated 22 cases of infant ALL with germline MLL using chemotherapy alone. The 5-year event-free survival rate was 95.5% with a 95% confidence interval of 86.9 to 100%. All 21 infants with precursor B-cell ALL have been in first complete remission for 3.5 to 8.8 years. Most treatment-related toxicities were predictable and well tolerated, and neither secondary malignancies nor physical growth impairments have been observed. These results indicate that chemotherapy of the type described here is both safe and highly effective against infant precursor B-cell ALL with MLL in the germline configuration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|